Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.01
NAS:TECH's Cash to Debt is ranked lower than
81% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:TECH: 1.01 )
Ranked among companies with meaningful Cash to Debt only.
NAS:TECH' s Cash to Debt Range Over the Past 10 Years
Min: 1.01  Med: 5014.03 Max: No Debt
Current: 1.01
Equity to Asset 0.78
NAS:TECH's Equity to Asset is ranked higher than
61% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:TECH: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
NAS:TECH' s Equity to Asset Range Over the Past 10 Years
Min: 0.78  Med: 0.91 Max: 0.97
Current: 0.78
0.78
0.97
Interest Coverage 86.95
NAS:TECH's Interest Coverage is ranked lower than
73% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:TECH: 86.95 )
Ranked among companies with meaningful Interest Coverage only.
NAS:TECH' s Interest Coverage Range Over the Past 10 Years
Min: 86.15  Med: No Debt Max: No Debt
Current: 86.95
F-Score: 3
Z-Score: 11.73
M-Score: -2.43
WACC vs ROIC
7.94%
11.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 30.18
NAS:TECH's Operating margin (%) is ranked higher than
92% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:TECH: 30.18 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:TECH' s Operating margin (%) Range Over the Past 10 Years
Min: 30.18  Med: 54.2 Max: 58.1
Current: 30.18
30.18
58.1
Net-margin (%) 20.94
NAS:TECH's Net-margin (%) is ranked higher than
89% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:TECH: 20.94 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:TECH' s Net-margin (%) Range Over the Past 10 Years
Min: 20.94  Med: 37.16 Max: 40.8
Current: 20.94
20.94
40.8
ROE (%) 12.22
NAS:TECH's ROE (%) is ranked higher than
88% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:TECH: 12.22 )
Ranked among companies with meaningful ROE (%) only.
NAS:TECH' s ROE (%) Range Over the Past 10 Years
Min: 12.1  Med: 19.24 Max: 22.91
Current: 12.22
12.1
22.91
ROA (%) 9.37
NAS:TECH's ROA (%) is ranked higher than
90% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:TECH: 9.37 )
Ranked among companies with meaningful ROA (%) only.
NAS:TECH' s ROA (%) Range Over the Past 10 Years
Min: 9.37  Med: 18.28 Max: 22.16
Current: 9.37
9.37
22.16
ROC (Joel Greenblatt) (%) 61.85
NAS:TECH's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:TECH: 61.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:TECH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 61.85  Med: 110.2 Max: 120.19
Current: 61.85
61.85
120.19
Revenue Growth (3Y)(%) 16.70
NAS:TECH's Revenue Growth (3Y)(%) is ranked higher than
69% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NAS:TECH: 16.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:TECH' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.3  Med: 12.4 Max: 16.7
Current: 16.7
5.3
16.7
EBITDA Growth (3Y)(%) 3.10
NAS:TECH's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:TECH: 3.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:TECH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.8  Med: 11.6 Max: 41
Current: 3.1
1.8
41
EPS Growth (3Y)(%) -2.80
NAS:TECH's EPS Growth (3Y)(%) is ranked higher than
51% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. NAS:TECH: -2.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:TECH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.8  Med: 16.5 Max: 36.3
Current: -2.8
-2.8
36.3
» NAS:TECH's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

TECH Guru Trades in Q3 2015

George Soros 5,500 sh (New)
Ray Dalio 12,978 sh (New)
Chuck Royce 816,779 sh (+61.59%)
Ron Baron 1,400,394 sh (+33.13%)
Jim Simons 245,400 sh (+25.59%)
Ruane Cunniff 2,540 sh (unchged)
Jeremy Grantham Sold Out
Mairs and Power 1,293,524 sh (-6.09%)
Columbia Wanger 1,263,777 sh (-12.05%)
» More
Q4 2015

TECH Guru Trades in Q4 2015

Chuck Royce 908,569 sh (+11.24%)
Ron Baron 1,496,971 sh (+6.90%)
Mairs and Power 1,306,885 sh (+1.03%)
Ruane Cunniff 2,540 sh (unchged)
George Soros Sold Out
Columbia Wanger 847,288 sh (-32.96%)
Jim Simons 159,800 sh (-34.88%)
Ray Dalio 2,478 sh (-80.91%)
» More
Q1 2016

TECH Guru Trades in Q1 2016

Paul Tudor Jones 3,500 sh (New)
George Soros 18,000 sh (New)
Ron Baron 1,658,440 sh (+10.79%)
Columbia Wanger 851,260 sh (+0.47%)
Mairs and Power 1,310,574 sh (+0.28%)
Ruane Cunniff Sold Out
Ray Dalio Sold Out
Chuck Royce 834,759 sh (-8.12%)
Jim Simons 104,100 sh (-34.86%)
» More
Q2 2016

TECH Guru Trades in Q2 2016

Paul Tudor Jones 7,700 sh (+120.00%)
Mairs and Power 1,351,264 sh (+3.10%)
George Soros Sold Out
Ron Baron 1,642,221 sh (-0.98%)
Chuck Royce 766,259 sh (-8.21%)
Columbia Wanger 726,445 sh (-14.66%)
Jim Simons 39,800 sh (-61.77%)
» More
» Details

Insider Trades

Latest Guru Trades with TECH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ACAD, NAS:ICPT, NAS:IONS, NAS:ANAC, NAS:EXEL, NAS:CBPO, NAS:GLPG, OTCPK:BTGGF, NYSE:XON, NAS:JUNO, NAS:RARE, OTCPK:SOLTF, NAS:SRPT, NAS:KITE, NAS:GRFS, NAS:BLUE, OTCPK:LBTSF, NAS:ARIA, NAS:NKTR, NAS:UTHR » details
Traded in other countries:TE1.Germany,
Bio-Techne Corp and its subsidiaries develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products. The Company's business segments are the Biotechnology, Clinical Controls and Protein Platforms divisions.

Bio-Techne Corp was founded as Research and Diagnostic Systems, Inc. (R&D Systems) in 1976. In November 2014, the company's name was changed from Techne Corporation to Bio-Techne Corporation. The Company and its subsidiaries develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products. The Company's business segments are the Biotechnology, Clinical Controls and Protein Platforms divisions. The Biotechnology segment supply's the proteins, such as cytokines, growth factors, immunoassays, antibodies and related reagents, to the biotechnology research community. It isolates and produces proteins in a pure form either from the native cells or through recombinant DNA technology. The Clinical Controls segment develops and manufactures controls and calibrators for instruments in the global clinical market. The Company offers a wide range of hematology controls and calibrators for both impedance and laser type cell counters. It also supply's hematology control products for use as proficiency testing tools by laboratory certifying authorities in a number of states and countries. The Protein Platforms segment develops, manufactures and sells tools to make protein analysis simpler, more quantitative and reproduceable. The Company sells its protein platforms products directly to customers located in North America, western Europe and Japan. It also sells through third party distributors in China, southern Europe and the rest of the world. The Company's competitors include GE Healthcare Life Sciences, BD Biosciences, Merck KGaA/EMD Chemicals, Inc., PeproTech, Inc., Santa Cruz Biotechnology, Inc., Abcam plc., Thermo Fisher Scientific, Inc., Cayman Chemical Company and Enzo Biochem, Inc, Abbott Diagnostics, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Streck, Inc., Siemens Healthcare Diagnostics Inc. and Sysmex Corporation, Bio-Rad Laboratories, GE Healthcare, Merck KGaA, PerkinElmer and Thermo Fisher Scientific. It operates in United States, Europe, China, Other Asia and Rest of world. The Company is subject to the medical device excise tax which was included as part of the Affordable Care Act.

Ratios

vs
industry
vs
history
P/E(ttm) 39.11
TECH's P/E(ttm) is ranked lower than
61% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 29.00 vs. TECH: 39.11 )
Ranked among companies with meaningful P/E(ttm) only.
TECH' s P/E(ttm) Range Over the Past 10 Years
Min: 16.78  Med: 27.09 Max: 41.13
Current: 39.11
16.78
41.13
PE(NRI) 39.11
TECH's PE(NRI) is ranked lower than
61% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TECH: 39.11 )
Ranked among companies with meaningful PE(NRI) only.
TECH' s PE(NRI) Range Over the Past 10 Years
Min: 16.78  Med: 27.09 Max: 41.13
Current: 39.11
16.78
41.13
Price/Owner Earnings (ttm) 34.97
TECH's Price/Owner Earnings (ttm) is ranked lower than
53% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 32.43 vs. TECH: 34.97 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TECH' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 17.03  Med: 26.38 Max: 36.69
Current: 34.97
17.03
36.69
P/B 4.62
TECH's P/B is ranked lower than
57% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. TECH: 4.62 )
Ranked among companies with meaningful P/B only.
TECH' s P/B Range Over the Past 10 Years
Min: 3.27  Med: 4.6 Max: 8.27
Current: 4.62
3.27
8.27
P/S 8.14
TECH's P/S is ranked higher than
61% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. TECH: 8.14 )
Ranked among companies with meaningful P/S only.
TECH' s P/S Range Over the Past 10 Years
Min: 6.63  Med: 9.04 Max: 12.71
Current: 8.14
6.63
12.71
PFCF 32.12
TECH's PFCF is ranked lower than
55% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 28.22 vs. TECH: 32.12 )
Ranked among companies with meaningful PFCF only.
TECH' s PFCF Range Over the Past 10 Years
Min: 17.73  Med: 26.58 Max: 37.56
Current: 32.12
17.73
37.56
POCF 28.38
TECH's POCF is ranked lower than
58% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 23.11 vs. TECH: 28.38 )
Ranked among companies with meaningful POCF only.
TECH' s POCF Range Over the Past 10 Years
Min: 15.79  Med: 23.66 Max: 31.6
Current: 28.38
15.79
31.6
EV-to-EBIT 27.37
TECH's EV-to-EBIT is ranked lower than
56% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. TECH: 27.37 )
Ranked among companies with meaningful EV-to-EBIT only.
TECH' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.8  Med: 17 Max: 28.8
Current: 27.37
9.8
28.8
EV-to-EBITDA 21.25
TECH's EV-to-EBITDA is ranked lower than
52% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. TECH: 21.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
TECH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.4  Med: 16 Max: 22.4
Current: 21.25
9.4
22.4
PEG 16.83
TECH's PEG is ranked lower than
95% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.18 vs. TECH: 16.83 )
Ranked among companies with meaningful PEG only.
TECH' s PEG Range Over the Past 10 Years
Min: 1.01  Med: 2.67 Max: 19.59
Current: 16.83
1.01
19.59
Shiller P/E 36.11
TECH's Shiller P/E is ranked higher than
64% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 47.58 vs. TECH: 36.11 )
Ranked among companies with meaningful Shiller P/E only.
TECH' s Shiller P/E Range Over the Past 10 Years
Min: 24.39  Med: 33.42 Max: 56.47
Current: 36.11
24.39
56.47
Current Ratio 4.69
TECH's Current Ratio is ranked higher than
52% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. TECH: 4.69 )
Ranked among companies with meaningful Current Ratio only.
TECH' s Current Ratio Range Over the Past 10 Years
Min: 3.77  Med: 9.58 Max: 17.79
Current: 4.69
3.77
17.79
Quick Ratio 3.63
TECH's Quick Ratio is ranked lower than
54% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. TECH: 3.63 )
Ranked among companies with meaningful Quick Ratio only.
TECH' s Quick Ratio Range Over the Past 10 Years
Min: 3.35  Med: 8.79 Max: 16.31
Current: 3.63
3.35
16.31
Days Inventory 126.51
TECH's Days Inventory is ranked higher than
52% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. TECH: 126.51 )
Ranked among companies with meaningful Days Inventory only.
TECH' s Days Inventory Range Over the Past 10 Years
Min: 63.05  Med: 115.62 Max: 192.76
Current: 126.51
63.05
192.76
Days Sales Outstanding 68.31
TECH's Days Sales Outstanding is ranked lower than
55% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. TECH: 68.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
TECH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.81  Med: 45.11 Max: 68.31
Current: 68.31
40.81
68.31
Days Payable 46.43
TECH's Days Payable is ranked lower than
57% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. TECH: 46.43 )
Ranked among companies with meaningful Days Payable only.
TECH' s Days Payable Range Over the Past 10 Years
Min: 28.64  Med: 33.49 Max: 54.23
Current: 46.43
28.64
54.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.19
TECH's Dividend Yield is ranked higher than
50% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. TECH: 1.19 )
Ranked among companies with meaningful Dividend Yield only.
TECH' s Dividend Yield Range Over the Past 10 Years
Min: 0.39  Med: 1.46 Max: 1.82
Current: 1.19
0.39
1.82
Dividend Payout 0.46
TECH's Dividend Payout is ranked lower than
66% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. TECH: 0.46 )
Ranked among companies with meaningful Dividend Payout only.
TECH' s Dividend Payout Range Over the Past 10 Years
Min: 0.27  Med: 0.38 Max: 0.46
Current: 0.46
0.27
0.46
Dividend Growth (3y) 2.70
TECH's Dividend Growth (3y) is ranked lower than
61% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. TECH: 2.70 )
Ranked among companies with meaningful Dividend Growth (3y) only.
TECH' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 14
Current: 2.7
0
14
Forward Dividend Yield 1.18
TECH's Forward Dividend Yield is ranked higher than
51% of the 195 Companies
in the Global Biotechnology industry.

( Industry Median: 1.18 vs. TECH: 1.18 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.44
TECH's Yield on cost (5-Year) is ranked higher than
50% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 1.44 vs. TECH: 1.44 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TECH' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.47  Med: 1.77 Max: 2.2
Current: 1.44
0.47
2.2
3-Year Average Share Buyback Ratio -0.40
TECH's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. TECH: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TECH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: 0.3 Max: 2.4
Current: -0.4
-3.1
2.4

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 1095.00
TECH's Price/Net Current Asset Value is ranked lower than
100% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. TECH: 1095.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TECH' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 6.89  Med: 12.31 Max: 1127.7
Current: 1095
6.89
1127.7
Price/Tangible Book 29.59
TECH's Price/Tangible Book is ranked lower than
92% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. TECH: 29.59 )
Ranked among companies with meaningful Price/Tangible Book only.
TECH' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.15  Med: 6.37 Max: 30.47
Current: 29.59
4.15
30.47
Price/Projected FCF 1.85
TECH's Price/Projected FCF is ranked higher than
72% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.64 vs. TECH: 1.85 )
Ranked among companies with meaningful Price/Projected FCF only.
TECH' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.27  Med: 1.98 Max: 12.77
Current: 1.85
1.27
12.77
Price/DCF (Earnings Based) 3.65
TECH's Price/DCF (Earnings Based) is ranked lower than
95% of the 20 Companies
in the Global Biotechnology industry.

( Industry Median: 1.06 vs. TECH: 3.65 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.91
TECH's Price/Median PS Value is ranked higher than
60% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. TECH: 0.91 )
Ranked among companies with meaningful Price/Median PS Value only.
TECH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.52  Med: 1.02 Max: 2.89
Current: 0.91
0.52
2.89
Price/Graham Number 7.17
TECH's Price/Graham Number is ranked lower than
84% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 2.74 vs. TECH: 7.17 )
Ranked among companies with meaningful Price/Graham Number only.
TECH' s Price/Graham Number Range Over the Past 10 Years
Min: 1.97  Med: 2.92 Max: 10.85
Current: 7.17
1.97
10.85
Earnings Yield (Greenblatt) (%) 3.68
TECH's Earnings Yield (Greenblatt) (%) is ranked higher than
86% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. TECH: 3.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TECH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.5  Med: 5.9 Max: 10.2
Current: 3.68
3.5
10.2
Forward Rate of Return (Yacktman) (%) 5.06
TECH's Forward Rate of Return (Yacktman) (%) is ranked lower than
66% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 14.98 vs. TECH: 5.06 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TECH' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4.9  Med: 12.8 Max: 25.7
Current: 5.06
4.9
25.7

More Statistics

Revenue (TTM) (Mil) $499.0
EPS (TTM) $ 2.80
Beta0.86
Short Percentage of Float4.13%
52-Week Range $79.95 - 117.42
Shares Outstanding (Mil)37.30
» More Articles for NAS:TECH

Headlines

Articles On GuruFocus.com
Ron Baron's Stocks With Highest Returns Jul 13 2016 
Mairs and Power Sells Baxalta, Walt Disney, Target Dec 16 2015 
Baron Funds Comments on Bio-Techne Corp Nov 02 2015 
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
Chuck Akre MA, AMT, ESGR, ROST, TECH, KMB; Sells WRB, CRI, GLRE, RP, XOM Feb 13 2011 
Techne Corp. Reports Operating Results (10-Q) Feb 09 2011 
Techne Corp. Reports Operating Results (10-Q) Nov 09 2010 
Techne Corp. Reports Operating Results (10-K) Aug 27 2010 
Chuck Royce’s Top Predictable Companies: MEDNAX, Techne Corp., ITT Educational Services, Exactech May 17 2010 
Techne Corp. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
Bio-Techne Corp. breached its 50 day moving average in a Bearish Manner : TECH-US : September 26,... Sep 26 2016
Bio-Techne Announces Investor Day and Webcast Sep 15 2016
Bio-Techne Corp. breached its 50 day moving average in a Bullish Manner : TECH-US : September 9,... Sep 09 2016
ETF’s with exposure to Bio-Techne Corp. : September 6, 2016 Sep 06 2016
BIO-TECHNE CORP Financials Sep 02 2016
Bio-Techne Corp. : TECH-US: Dividend Analysis : August 29th, 2016 (record date) : By the numbers :... Sep 01 2016
Bio-Techne Announces Investor Day And Webcast Aug 31 2016
Bio-Techne Corp. :TECH-US: Earnings Analysis: 2016 By the Numbers : August 30, 2016 Aug 30 2016
BIO-TECHNE CORP Files SEC form 10-K, Annual Report Aug 29 2016
ETF’s with exposure to Bio-Techne Corp. : August 22, 2016 Aug 22 2016
Bio-Techne Corp. :TECH-US: Earnings Analysis: Q4, 2016 By the Numbers : August 19, 2016 Aug 19 2016
Edited Transcript of TECH earnings conference call or presentation 17-Aug-16 1:00pm GMT Aug 17 2016
BIO-TECHNE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Aug 17 2016
Bio-Techne Declares Dividend Aug 17 2016
Q4 2016 Bio-Techne Corp Earnings Release - Before Market Open Aug 17 2016
Bio-Techne Declares Dividend Aug 17 2016
Bio-Techne Releases Fourth Quarter Fiscal 2016 Results Aug 17 2016
Are You Watching Medpace's IPO? Don't Ignore Its Larger Rival Aug 12 2016
Medical Stocks' Earnings to Watch Next Week: TECH, WVE, EARS Aug 12 2016
PRA Health Sciences Vs. Medpace: How 2 Medical IPOs Stack Up Aug 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)